

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/475,784
Filed : June 7, 1995
Page 2

applicants' right to pursue the subject matter of this claim in a later-filed application. Please amend claim 95 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

- 95. (Amended) A method of [preventing or] treating a cancer in a subject which comprises administering to the subject an effective cancer [preventing or] treating amount of a composition which comprises:
- a) a conjugate of i) a ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin or a derivative thereof comprising an e-aminolysyl group;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject;
- wherein the ganglioside derivative is a derivative of a ganglioside selected from the group consisting of GM2, GM3, GD3, GD3 lactone, O-acetyl GD3 and GT3; and
- wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin or the derivative thereof through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the e-aminolysyl group of Keyhole Limpet Hemocyanin or the derivative thereof, so as to thereby [prevent or] treat a cancer in the subject.--
- Sub
Is
H'